Charles River Laboratories and Ori Biotech, a manufacturing technology company with hubs in London and Philadelphia, jointly announced some results of a collaboration that began earlier in 2024, with Charles River using Ori’s next-generation cell and gene therapy manufacturing platform, known as IRO. Head-to-head process runs compared IRO’s biological performance to a process optimized by Charles River specifically for chimeric antigen receptor (CAR)-T cell therapy, over two years, with an alternative manufacturing technology. Source: Biopharm International 24/9/2024